Bubser, Michael2; Bridges, Thomas M3; Dencker, Ditte4; Gould, Robert W3; Grannan, Michael3; Noetzel, Meredith J3; Lamsal, Atin3; Niswender, Colleen M3; Daniels, J Scott3; Poslusney, Michael S3; Melancon, Bruce J3; Tarr, James C3; Byers, Frank W3; Wess, Jürgen3; Duggan, Mark E3; Dunlop, John3; Wood, Michael W3; Brandon, Nicholas J3; Wood, Michael R3; Lindsley, Craig W3; Conn, P Jeffrey3; Jones, Carrie K3
1 Neuropsykiatrisk laboratorium, Psykiatrisk Center København, Mental Health Services, The Capital Region of Denmark2 Department of Pharmacology, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States.3 unknown4 Radiologisk Klinik, Diagnostisk Center, Rigshospitalet, The Capital Region of Denmark
Positive allosteric modulators (PAMs) of the M4 muscarinic acetylcholine receptor (mAChR) represent a novel approach for the treatment of psychotic symptoms associated with schizophrenia and other neuropsychiatric disorders. We recently reported that the selective M4 PAM VU0152100 produced an antipsychotic drug-like profile in rodents after amphetamine challenge. Previous studies suggest that enhanced cholinergic activity may also improve cognitive function and reverse deficits observed with reduced signaling through the N-methyl-d-aspartate subtype of the glutamate receptor (NMDAR) in the central nervous system. Prior to this study, the M1 mAChR subtype was viewed as the primary candidate for these actions relative to the other mAChR subtypes. Here we describe the discovery of a novel M4 PAM, VU0467154, with enhanced in vitro potency and improved pharmacokinetic properties relative to other M4 PAMs, enabling a more extensive characterization of M4 actions in rodent models. We used VU0467154 to test the hypothesis that selective potentiation of M4 receptor signaling could ameliorate the behavioral, cognitive, and neurochemical impairments induced by the noncompetitive NMDAR antagonist MK-801. VU0467154 produced a robust dose-dependent reversal of MK-801-induced hyperlocomotion and deficits in preclinical models of associative learning and memory functions, including the touchscreen pairwise visual discrimination task in wild-type mice, but failed to reverse these stimulant-induced deficits in M4 KO mice. VU0467154 also enhanced the acquisition of both contextual and cue-mediated fear conditioning when administered alone in wild-type mice. These novel findings suggest that M4 PAMs may provide a strategy for addressing the more complex affective and cognitive disruptions associated with schizophrenia and other neuropsychiatric disorders.
A C S Chemical Neuroscience, 2014, Vol 5, Issue 10, p. 920-42